The CCDC137 Knockout HeLa Polyclonal Cells product comprises a heterogeneous population of HeLa cells subjected to CRISPR/Cas9-mediated disruption of the CCDC137 gene. This polyclonal knockout cell pool provides a loss-of-function model for investigating the biological role of CCDC137 without the bias of single-cell clonal selection. The population-based knockout strategy preserves the genetic diversity of the parental line, offering a robust and cost-effective means to assess CCDC137 function in a cancer-relevant context.
HeLa cells are a widely employed immortalized cell line derived from a human cervical adenocarcinoma. These cells harbor integrated HPV18 sequences and exhibit a highly aneuploid karyotype with robust proliferative capacity, making them a versatile platform for studying gene function in an epithelial cancer context. Their rapid doubling time and ease of transfection further enhance their utility in transient and stable genetic manipulation experiments.
CCDC137 encodes a protein containing predicted coiled-coil domains, which typically mediate protein-protein interactions. Although its precise molecular function remains uncharacterized, CCDC137 is predicted to participate in cytoskeletal dynamics or ciliary processes through association with microtubule-based structures. Such domains often form extended helical structures involved in oligomerization and subcellular targeting, and based on domain architecture, CCDC137 may localize to centrosomes or ciliary axonemes. It is hypothesized to interact with other coiled-coil domain-containing proteins, potentially serving as a scaffold or adaptor in these pathways. Knockout of CCDC137 may therefore disrupt putative protein complexes required for proper cytoskeletal organization or ciliary assembly, though validation remains necessary.
Disruption of CCDC137 in HeLa cells enables interrogation of its potential roles in cell morphology, proliferation, and migration, which are central to cancer cell biology. HeLa cells, with their transformed phenotype, provide a relevant background to explore potential roles of CCDC137 in oncogenic processes. Since the gene has no reported disease association, these studies may reveal novel links to cancer cell proliferation or invasiveness. Given the genetic complexity of HeLa cells, this knockout model offers a system to uncover phenotypic consequences that may be masked in normal cell types, thereby facilitating elucidation of CCDC137??s contribution to epithelial tumor cell behavior.
Researchers can employ this polyclonal cell pool in a variety of experimental approaches, including immunofluorescence staining for cytoskeletal or ciliary markers (e.g., acetylated tubulin, pericentrin), Western blotting to confirm target protein depletion, and proliferation, migration, and invasion assays to assess cancer-relevant phenotypes. RNA-sequencing can profile transcriptomic changes induced by CCDC137 loss, while co-immunoprecipitation experiments may help identify interacting partners, advancing the functional annotation of CCDC137. For additional technical information, please contact Ascent Research.
